Download full announcement Renalytix AI plc (AIM: RENX), the AIM quoted developer of artificial intelligence-enabled diagnostics for kidney disease, announces its inaugural unaudited interim results for the six months ended 31 December 2018. Operational highlights Secured agreements for
Download full announcement Investigators include leading transplant clinicians from Emory University, the University of Manitoba, the Westmead Hospital Sydney, and Icahn School of Medicine at Mount Sinai. Renalytix AI plc(LON: RENX), a developer of artificial intelligence-enabled clinical
Download full announcement Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled diagnostics for kidney disease, announces that it will host investor briefings focused on AI-enabled diagnostics and kidney disease on Monday 25 March 2019.
Download full announcement Further to the announcement on 20 December 2018, Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled diagnostics for kidney disease, announces the appointment of Stifel as the Company’s nominated adviser and joint broker with immediate effect.
Download full announcement Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled diagnostics for kidney disease, announces the completion of a joint venture partnership agreement with AKESOgen, an industry-leading commercial laboratory facility and provider of clinical
Company Adds Clinical and Data Security Expertise to Support KidneyIntelX Clinical Validation, Software and Regulatory Programmes Download full announcement Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled diagnostics for kidney disease, announces the expansion of its
Validation study to assess approximately 5,000 patients with participation from a multi-center group of leading U.S. investigators Download full announcement Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled diagnostics for kidney disease, announces the start of its
Download full announcement This announcement relates solely to ordinary shares in the Company which were distributed to certain qualifying shareholders owning EKF Diagnostic Holdings plc shares prior to admission (the “Distribution Shares”). Holders of Distribution Shares are reminded that these
Download full announcement Renalytix AI plc (AIM: RENX), a developer of artificial intelligence (“AI”) enabled clinical diagnostics solutions for kidney disease, announces the exercise of its option, as described in the Company’s admission document, for the exclusive license from the Icahn
Download full announcement The Company was informed that today, Christopher Mills, a non-executive director, completed the purchase of 3,168 ordinary shares of 0.25 pence each (“Ordinary Shares”) in the Company at a price of 112 pence per share. Following this purchase, Mr Mills is interested in
